| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $11.3M | — | +161.8% |
| SG&A Expense | $6.9M | — | +31.5% |
| Operating Income | -$17.2M | — | -80.5% |
| Net Income | -$32.9M | — | -260.4% |
| EPS (Basic) | -$1.73 | — | -652.2% |
| EPS (Diluted) | -$1.73 | — | -652.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $32.8M | -52.6% | +24.3% |
| Short-term Investments | $34.8M | +82.9% | +240.0% |
| Current Assets | $69.2M | -22.6% | +73.6% |
| Total Assets | $71.6M | -22.3% | +64.5% |
| Current Liabilities | $6.7M | -86.0% | +21.4% |
| Total Liabilities | $22.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$20.9M | — | -42.5% |
| Investing Cash Flow | -$15.5M | — | -111.4% |
| +260.5% |
| Stockholders' Equity | $49.3M | +77.4% | +32.1% |